Display options
Cite
Chockalingam R, Downing C, Tyring SK. Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients. J Clin Med. 2015;4(6):1229-39doi: 10.3390/jcm4061229.
Chockalingam, R., Downing, C., & Tyring, S. K. (2015). Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients. Journal of clinical medicine, 4(6), 1229-39. https://doi.org/10.3390/jcm4061229
Chockalingam, Ramya, et al. "Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients." Journal of clinical medicine vol. 4,6 (2015): 1229-39. doi: https://doi.org/10.3390/jcm4061229
Chockalingam R, Downing C, Tyring SK. Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients. J Clin Med. 2015 Jun 03;4(6):1229-39. doi: 10.3390/jcm4061229. PMID: 26239556; PMCID: PMC4484997.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2015 Jun 03;4(6):1229-39. doi: 10.3390/jcm4061229.

Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients.

Journal of clinical medicine

Ramya Chockalingam, Christopher Downing, Stephen K Tyring

Affiliations

  1. Medical School, the University of Texas Health Science Center at Houston, 6431 Fannin, Houston, TX 77030, USA. [email protected].
  2. Center for Clinical Studies, 1401 Binz, Suite 200, Houston, TX 77004, USA. [email protected].
  3. Center for Clinical Studies, 1401 Binz, Suite 200, Houston, TX 77004, USA. [email protected].
  4. Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA. [email protected].

PMID: 26239556 PMCID: PMC4484997 DOI: 10.3390/jcm4061229

Abstract

Non-melanoma skin cancers represent a major cause of morbidity after organ transplantation. Squamous cell carcinomas (SCC) are the most common cutaneous malignancies seen in this population, with a 65-100 fold greater incidence in organ transplant recipients compared to the general population. In recent years, human papillomaviruses (HPV) of the beta genus have been implicated in the pathogenesis of post-transplant SCCs. The underlying mechanism of carcinogenesis has been attributed to the E6 and E7 proteins of HPV. Specific immunosuppressive medications, such as the calcineurin inhibitors and azathioprine, are associated with a higher incidence of post-transplant SCCs compared to other immunosuppressive agents. Compared to other immunosuppressives, mTOR inhibitors and mycophenolate mofetil have been associated with a decreased risk of developing post-transplant non-melanoma skin cancers. As a result, they may represent ideal immunosuppressive medications in organ transplant recipients. Treatment options for post-transplant SCCs include surgical excision, Mohs micrographic surgery, systemic retinoid therapy, adjunct topical therapy, electrodessication and curettage, and radiation therapy. This review will discuss the epidemiology, risk factors, and management options of post-transplant SCCs. In addition, the underlying mechanisms of beta-HPV mediated carcinogenesis will be discussed.

Keywords: human papillomavirus (HPV); organ transplant; skin cancer; squamous cell carcinoma

References

  1. Virology. 2015 May;479-480:290-6 - PubMed
  2. EMBO J. 2011 Nov 16;30(22):4571-85 - PubMed
  3. Int J Cancer. 2013 Mar 15;132(6):1429-38 - PubMed
  4. Virology. 2012 Mar 15;424(2):77-98 - PubMed
  5. Br J Cancer. 2003 Oct 6;89(7):1221-7 - PubMed
  6. Int J Cancer. 2016 Jan 15;138(2):281-92 - PubMed
  7. Cancer Treat Rev. 2014 Mar;40(2):205-14 - PubMed
  8. Br J Dermatol. 2000 Sep;143(3):513-9 - PubMed
  9. Ecancermedicalscience. 2015 Apr 29;9:526 - PubMed
  10. J Am Acad Dermatol. 2011 Aug;65(2):263-79; quiz 280 - PubMed
  11. J Virol. 2008 Apr;82(8):3894-902 - PubMed
  12. J Am Acad Dermatol. 2005 Aug;53(2):253-60 - PubMed
  13. Clin Transplant. 2015 Feb;29(2):110-7 - PubMed
  14. PLoS Pathog. 2012;8(7):e1002807 - PubMed
  15. Exp Dermatol. 2007 Jul;16(7):590-9 - PubMed
  16. Cancer Res. 2005 Mar 15;65(6):2216-23 - PubMed
  17. Transplant Proc. 2006 Oct;38(8):2505-7 - PubMed
  18. Nature. 2009 Jul 2;460(7251):108-12 - PubMed
  19. N Engl J Med. 2012 Jul 26;367(4):329-39 - PubMed
  20. Presse Med. 2014 Dec;43(12 Pt 2):e435-43 - PubMed
  21. Rev Med Virol. 2015 Mar;25 Suppl 1:2-23 - PubMed
  22. Virology. 2010 May 25;401(1):70-9 - PubMed
  23. Adv Exp Med Biol. 2014;810:192-207 - PubMed
  24. PLoS Pathog. 2011 Jul;7(7):e1002125 - PubMed
  25. J Gen Virol. 2012 Jan;93(Pt 1):165-74 - PubMed
  26. Nephrol Dial Transplant. 2003 Jun;18(6):1052-8 - PubMed
  27. Arch Dermatol. 2003 Mar;139(3):301-6 - PubMed
  28. Transplant Res. 2015 Jan 14;4:1 - PubMed
  29. Immunity. 2009 Jun 19;30(6):832-44 - PubMed
  30. J Virol. 2014 Aug;88(15):8201-12 - PubMed
  31. J Virol. 2012 Dec;86(24):13174-86 - PubMed
  32. Cancer Med. 2014 Oct;3(5):1440-7 - PubMed
  33. Int J Cancer. 2009 Oct 15;125(8):1747-54 - PubMed
  34. J Virol. 2003 Feb;77(3):2195-206 - PubMed
  35. Oncogene. 2008 May 1;27(20):2923-8 - PubMed
  36. FASEB J. 2008 Feb;22(2):622-32 - PubMed
  37. Mol Cell Biol. 1994 Dec;14(12):8250-8 - PubMed
  38. PLoS Pathog. 2012;8(6):e1002761 - PubMed
  39. J Heart Lung Transplant. 2006 Oct;25(10 ):1186-91 - PubMed
  40. J Virol. 2013 Nov;87(22):12158-65 - PubMed

Publication Types